medigraphic.com

2023, Number 1

<< Back

Rev Cuba Endoc 2023; 34 (1)

Beneficial effects of insulin icodec and its possible use in people with diabetes mellitus

Hernández RJ

Language: Spanish
References: 40
Page:
PDF size: 411.17 Kb.


ABSTRACT

Introduction: The development and possible use, once a week, of a new ultra-long-acting insulin analogue (icodec) would allow to cover the needs of basal insulin in those patients who require it.
Objective: To describe the beneficial effects of insulin icodec and its possible use in people with diabetes mellitus.
Methods: A literature review was carried out, using search engines from Google Scholar, SciELO and PubMed databases. The keywords used were insulin; icodec; treatment; and diabetes mellitus. Review and research paperworks and websites, which were generally less than 5 years old, were reviewed in Spanish, Portuguese and English, which referred to the topic of study through the title. Abstracts were examined and articles were analysed which, due to their quality, could respond to the objective set at the author's discretion. This allowed the consultation of 74 articles, of which 40 were referenced.
Conclusions: Insulin icodec has a half-long life that allows to cover the basal insulin needs of people with diabetes mellitus for approximately one week. Different studies have shown its non-inferiority in the reduction of glycated hemoglobin when compared to other drugs, together with the criterion that it seems to have a safe and well-tolerated profile. This should allow its possible use in people with diabetes mellitus.


REFERENCES

  1. Guías Asociación Latinoamericana de Diabetes (ALAD) sobre el Diagnóstico, Control y Tratamiento de la Diabetes Mellitus Tipo 2 con Medicina Basada en Evidencia. Ed. 2019. Rev. de la ALAD. 2020 [acceso 06/05/2023]. Disponible en: http://www.revistaalad.com/guias/5600AX191_guias_alad_2019.pdf

  2. Ogle GD, James S, Dabelea D, Pihoker C, Svennson J, Maniam J, et al. Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas. Diabetes research and clinical practice. 2022 [acceso 06/05/2023];183:109083. Disponible en: https://www.sciencedirect.com/science/article/pii/S0168822721004423

  3. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan B, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes research and clinical practice. 2022 [acceso 06/05/2023];183:109-19. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0168822721004782

  4. Organización Panamericana de la Salud. Panorama de la diabetes en la Región de las Américas. Washington, D.C.: OPS; 2023. [acceso 06/05/2023]. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/57197/9789275326336_spa.pdf?sequence=1&isAllowed=y

  5. Zerda GK. Manejo de las complicaciones agudas de diabetes en servicios de emergencias. Digital – UMSS. 2022 [acceso 06/05/2023]. Disponible en: http://ddigital.umss.edu.bo:8080/jspui/handle/123456789/35458

  6. American Diabetes Association. Introduction: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 [acceso 06/05/2023];45(Sup 1):S1-S2. Disponible en: https://www.biogenetech.co.th/wp-content/uploads/2021/12/ADA-Guideline-2022.pdf

  7. Ferreira CMSN, Souto D, Navarro GV, da Silva MTD, Rodrigues MLM, Serejo MN, et al. Diabetes mellitus tipo 1: uma revisão da literatura / Type 1 diabetes mellitus: a review of the literature. Braz. J. Develop. 2020 [acceso 06/05/2023];8(5):37158-67. Disponible en: https://ojs.brazilianjournals.com.br/ojs/index.php/BRJD/article/view/47992

  8. Nishimura E, Pridal L, Glendorf T, Hansen BF, HubálekF, Kjeldsen F, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care. 2021 [acceso 06/05/2023];9(1):e002301. Disponible en: https://drc.bmj.com/content/bmjdrc/9/1/e002301.full.pdf

  9. Polonsky WH, Arora R, Faurby M, Fernandes J, Liebl A. Higher rates of persistence and adherence in patients with type 2 diabetes initiating once-weekly vs daily injectable glucagon-like peptide-1 receptor agonists in us clinical practice (STAY study). Diabetes Ther. 2022 [acceso 06/05/2023];13(1):175-87. Disponible en: https://link.springer.com/article/10.1007/s13300-021-01189-6

  10. Hernández J. Algunas características del tratamiento con insulina en el paciente con diabetes mellitus tipo 2. Revista Cubana de Medicina General Integral. 2022 [acceso 06/05/2023];38(4). Disponible en: https://revmgi.sld.cu/index.php/mgi/article/view/1836

  11. Gómez F, Carrasco FJ, Pérez A, Escalada J, Álvarez F, Miranda C, et al. Resumen ejecutivo sobre el tratamiento de la diabetes mellitus tipo 2 en personas de edad avanzada o frágiles. Actualización 2022 del documento de consenso 2018 «Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano». Revista Clínica Española. 2022 [acceso 06/05/2023];222(8):496-9. Disponible en: https://www.sciencedirect.com/science/article/pii/S0014256522000686#bib0105

  12. Jiménez JG, Villegas M, ML Carvajal. Conceptos Actuales de la Terapia con Insulina. Revista Ciencia y Salud Integrando Conocimientos. 2022 [acceso 26/05/2023];6(3):65-78. Disponible en: https://www.revistacienciaysalud.ac.cr/ojs/index.php/cienciaysalud/article/view/416/538

  13. Mata M. Tipos de insulina. Diabetes Práctica. 2017 [acceso 26/05/2023];08(Supl Extr 4):1-24. Disponible en: https://www.redgdps.org/gestor/upload/colecciones/1509468544.sp-8-4.pdf

  14. Illescas KH, Castro CM, Carrera MK, García MF. Insulinoterapia en pacientes con diabetes mellitus tipo 2. RECIAMUC. 2019 [acceso 26/05/2023];3(2):875-94. Disponible en: https://reciamuc.com/index.php/RECIAMUC/article/view/370/383

  15. Jerez CI, Medina YA, Ortiz AS, González SI, Aguirre MC. Fisiopatología y alteraciones clínicas de la diabetes mellitus tipo 2: revisión de literatura. NOVA publ. Cient. 2022 [acceso 26/05/2023];20(3):65-103. Disponible en: https://hemeroteca.unad.edu.co/index.php/nova/article/view/6184/5836

  16. American Diabetes Association Professional Practice Committee. 9 Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 [acceso 26/05/2023];45(Supl 1):125-43. Disponible en: https://diabetesjournals.org/care/article/45/Supplement_1/S125/138908/9-Pharmacologic-Approaches-to-Glycemic-Treatment

  17. Holt RI, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS., Klupa T, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021 [acceso 26/05/2023];44(11):2589-625. Disponible en: https://diabetesjournals.org/care/article/44/11/2589/138492/The-Management-of-Type-1-Diabetes-in-Adults-A

  18. Guillen E, Valles JA. Análogos de la insulina. ¿Cuál es su lugar en la terapéutica? FMC - Formación Médica Continuada en Atención Primaria. 2022 [acceso 26/05/2023];29(5):268-75. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1134207222000615

  19. Danne T, Matsuhisa M, Sussebach C, Goyeau H, Lauand F, Niemoeller E, et al. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: a meta-analysis of 6-month phase 3 clinical trials. Diabetes Obes Metab. 2020 [acceso 26/05/2023];22(10):1880-5. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540568/

  20. Lane W, Bailey TS, Gerety G, Gumprecht J, Philis A, Thim Ch, et al. Group Information; SWITCH 1. Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017 [acceso 26/05/2023];318(1):33-44. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817477/

  21. Sandoval DC, Socasi EG, Vera EM, Poaquiza DJ. El uso de insulina en pacientes con diabetes tipo II. RECIAMUC. 2023 [acceso 16/01/2023];7(2):124-33. Disponible en: https://www.reciamuc.com/index.php/RECIAMUC/article/view/1098/1742

  22. Blanco EG, Chavarría GF, Garita YM. Insulinización práctica en la diabetes mellitus tipo 2. Revista Médica Sinergia. 2021 [acceso 16/01/2023];6(01):1-11. Disponible en: https://www.medigraphic.com/pdfs/sinergia/rms-2021/rms211d.pdf

  23. Rozas PJ, Merchante A, Gorgojo JJ. Simplificación en el tratamiento con insulina en personas con DM2. Suplemento medico interactivo. 2020 [acceso 16/01/2023]. Disponible en: https://elmedicointeractivo.com/wp-content/uploads/2022/06/192EEB1.pdf

  24. Girbés J, Escalada J, Mata M, Gómez F, Artola S, Fernández D, et al. Consenso sobre el tratamiento con insulina en la diabetes tipo 2. Endocrinol Diabetes Nutr. 2018 [acceso 16/01/2023]:9. Disponible en: https://www.sefac.org/sites/default/files/2018-03/consenso20tratamiento20insulina20GirbC3A9s20SED20EDN18.pdf

  25. Fernández E. Novedades en diabetes tipo 1 aportadas en el Congreso de la EASD 2022. [acceso 16/01/2023]. Disponible en: https://www.revistadiabetes.org/wp-content/uploads/Highlights-Congreso-Asociacion-Europea-para-el-estudio-de-la-diabetes-EASD-2022.pdf

  26. López F, Cols C, Mediavilla JJ, Cañís J, Hernández C, Gonzalez MB. Actualización en el uso de insulinas para el médico de familia. Medicina de Familia. SEMERGEN. 2022 [acceso 16/01/2023];48(1):54-62. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1138359321001398

  27. DiMarchi RD, Mayer JP. Icodec Advances the Prospect of Once-Weekly Insulin Injection. J. Med. Chem. 2021 [acceso 16/01/2023];64(13):8939-41. DOI: https://doi.org/10.1021/acs.0000jmedchem.1c00983

  28. Nishimura E, Kjeldsen T, Hubalek F, Glendorf T, Stidsen CE, Hansen BF, et al. 236-OR: molecular and biological properties of insulin icodec, a new insulin analog designed to give a long half-life suitable for once-weekly dosing. Diabetes. 2020 [acceso 16/01/2023];69(Supl_1):236-OR. Disponible en: https://diabetesjournals.org/diabetes/article/69/Supplement_1/236-OR/56809/236-OR-Molecular-and-Biological-Properties-of

  29. Kjeldsen TB, Hubálek F, Hjørringgaard CU, Tagmose TM, Nishimura E, Stidsen CE, et al. Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans. J. Med. Chem. 2021 [acceso 16/01/2023];64(13):8942-50. Disponible en: https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00257

  30. Kjeldsen TB, Hubálek F, Tagmose TM, Pridal L, Refsgaard HHF, Porsgaard T, et al. Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320. J. Med. Chem. 2021 [acceso 16/01/2023];64(1):616-28. Disponible en: https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01576

  31. Hovelmann U, Brondsted L, Kristensen NR, Ribel R, Devries JH, Heiset T, et al. 237-OR: Insulin Icodec: An Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes. Diabetes. 2020 [acceso 26/01/2023];69 (Suppl_1):237-OR. Disponible en: https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0042-1746280

  32. Rosenstock J, Kjaersgaard MI, Moller D, Hansen MV, Goldenberg R. 238-OR: Once-Weekly Basal Insulin Icodec Offers Comparable Efficacy and Safety vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve Patients with T2D Inadequately Controlled on OADS. Diabetes. 2020 [acceso 26/01/2023];69(Suppl_1):238-OR. Disponible en: https://diabetesjournals.org/diabetes/article/69/Supplement_1/238-OR/56838

  33. Lingvay I, Buse JB, Franek E, Hansen MV, Koefoed MM, Mathieu C, et al. A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100. Diabetes Care. 2021 [acceso 26/01/2023];44(7):1595-603. Disponible en: https://diabetesjournals.org/care/article/44/7/1595/138812/A-Randomized-Open-Label-Comparison-of-Once-Weekly

  34. Segner A, Rosenstock J, Kjærsgaard MI, Møller D, Hansen MV, Goldenberg R. Once-Weekly Basal Insulin Icodec Offers Comparable Efficacy and Safety vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve Patients with T2D Inadequately Controlled on OADS. Diabetologie und Stoffwechsel. 2022 [acceso 26/01/2023];17(S1):22. Disponible en: https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0042-1746281

  35. Philis‐Tsimikas A, Bajaj HS, Begtrup K, Cailleteau R, Gowda A, Lingvay I, et al. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once‐weekly insulin icodec in diabetes. Diabetes, Obesity and Metabolism. 2023 [acceso 26/01/2023];25(2):331-41. Disponible en: https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.14871

  36. Novo Nordisk. Company announcement. Once-weekly insulin icodec demonstrates superior reduction in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 phase 3a trial. Denmark: Novo Nordisk; 2022 [acceso 26/01/2023]. Disponible en: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=112839

  37. Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1. Denmark: Novo Nordisk; 2022 [acceso 26/01/2023]. Disponible en: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=118349

  38. Novo Nordisk. Company announcement. Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3. Denmark: Novo Nordisk; 2022 [acceso 26/01/2023]. Disponible en: https://n9.cl/zm2dg

  39. Philis-Tsimikas A, Asng M, Franek E, Jia T, Rosenstock, J, Stachlewska K, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. The Lancet Diabetes & Endocrinology. 2023 [acceso 26/01/2023];11(6):414-25. Disponible en: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00093-1/fulltext

  40. Novo Nordisk. Company announcement. Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial. Denmark: Novo Nordisk; 2022 [acceso 26/01/2023]. Disponible en: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=138024




2020     |     www.medigraphic.com